Market Cap 12.31M
Revenue (ttm) 120,000.00
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,891.67%
Debt to Equity Ratio 0.00
Volume 150,400
Avg Vol 161,994
Day's Range N/A - N/A
Shares Out 10.09M
Stochastic %K 29%
Beta 1.99
Analysts Strong Buy
Price Target $17.50

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 538 8200
Fax: 609 452 6467
Address:
29 Emmons Drive, Suite B-10, Princeton, United States
NetworkNewsWire
NetworkNewsWire Mar. 20 at 7:45 PM
$SNGX Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation https://ibn.fm/c1mtb
0 · Reply
TheFinalBet
TheFinalBet Mar. 19 at 10:15 PM
$SNGX Strong clinical signals
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 19 at 2:47 PM
MissionIRNewsBreaks – $SNGX Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication https://ibn.fm/x8lZl
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 19 at 2:47 PM
BioMedNewsBreaks — $SNGX Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points https://ibn.fm/wYVlS
0 · Reply
Slide3
Slide3 Mar. 19 at 12:44 PM
$SNGX Expert opinion Topical synthetic hypericin is a significant advancement for early-stage CTCL. Its excellent safety profile, proven efficacy, and non-mutagenic mechanism position it as a valuable first-line option. Minimal local adverse events and limited systemic absorption offer a key long-term safety advantage over conventional phototherapies. Its effectiveness in both patch and plaque lesions makes it a versatile tool, improving outcomes and quality of life for patients. https://www.tandfonline.com/doi/full/10.1080/13543784.2026.2643305#abstract
0 · Reply
DARKP00L
DARKP00L Mar. 19 at 11:41 AM
$SNGX 07:36 on Mar. 19 2026 Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs #tradeideas
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 18 at 6:41 PM
$SNGX Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline https://ibn.fm/opSRD
0 · Reply
rrch
rrch Mar. 17 at 2:11 PM
$SNGX looking for a new European partner
0 · Reply
Goldwave9
Goldwave9 Mar. 16 at 3:02 PM
$BBAI $VWAVW $SNGX in all of them, but expect nothing in the next three minutes. :)
1 · Reply
StrykerTactics
StrykerTactics Mar. 14 at 7:53 AM
$SBEV Earlier in the year, the company announced that Señor Frog’s selected Chispo Tequila as its house brand for several US and Caribbean locations. $SNGX The company announced that SGX945 (dusquetide) received the Promising Innovative Medicine (PIM)
0 · Reply
Latest News on SNGX
Soligenix to Present at BIO Investment & Growth Summit

Feb 24, 2026, 7:30 AM EST - 24 days ago

Soligenix to Present at BIO Investment & Growth Summit


Soligenix Details Recent Progress and Upcoming Milestones

Feb 12, 2026, 7:30 AM EST - 5 weeks ago

Soligenix Details Recent Progress and Upcoming Milestones


Soligenix Announces Closing of $7.5 Million Public Offering

Sep 29, 2025, 4:05 PM EDT - 6 months ago

Soligenix Announces Closing of $7.5 Million Public Offering


Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 6 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering


Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 1:03 PM EDT - 7 months ago

Why Is Soligenix Stock Soaring On Monday?


IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.


Soligenix to Present at BIO CEO & Investor Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference


Soligenix to Present at Upcoming Investor Conferences

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences


Soligenix Invited to Present at Upcoming Investor Conferences

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences


NetworkNewsWire
NetworkNewsWire Mar. 20 at 7:45 PM
$SNGX Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation https://ibn.fm/c1mtb
0 · Reply
TheFinalBet
TheFinalBet Mar. 19 at 10:15 PM
$SNGX Strong clinical signals
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 19 at 2:47 PM
MissionIRNewsBreaks – $SNGX Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication https://ibn.fm/x8lZl
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 19 at 2:47 PM
BioMedNewsBreaks — $SNGX Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points https://ibn.fm/wYVlS
0 · Reply
Slide3
Slide3 Mar. 19 at 12:44 PM
$SNGX Expert opinion Topical synthetic hypericin is a significant advancement for early-stage CTCL. Its excellent safety profile, proven efficacy, and non-mutagenic mechanism position it as a valuable first-line option. Minimal local adverse events and limited systemic absorption offer a key long-term safety advantage over conventional phototherapies. Its effectiveness in both patch and plaque lesions makes it a versatile tool, improving outcomes and quality of life for patients. https://www.tandfonline.com/doi/full/10.1080/13543784.2026.2643305#abstract
0 · Reply
DARKP00L
DARKP00L Mar. 19 at 11:41 AM
$SNGX 07:36 on Mar. 19 2026 Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs #tradeideas
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 18 at 6:41 PM
$SNGX Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline https://ibn.fm/opSRD
0 · Reply
rrch
rrch Mar. 17 at 2:11 PM
$SNGX looking for a new European partner
0 · Reply
Goldwave9
Goldwave9 Mar. 16 at 3:02 PM
$BBAI $VWAVW $SNGX in all of them, but expect nothing in the next three minutes. :)
1 · Reply
StrykerTactics
StrykerTactics Mar. 14 at 7:53 AM
$SBEV Earlier in the year, the company announced that Señor Frog’s selected Chispo Tequila as its house brand for several US and Caribbean locations. $SNGX The company announced that SGX945 (dusquetide) received the Promising Innovative Medicine (PIM)
0 · Reply
km1663
km1663 Mar. 13 at 1:29 PM
$SNGX Very last line of article, "With no changes to our model, our valuation remains at $25 per share."
0 · Reply
rrch
rrch Mar. 13 at 1:16 PM
$SNGX still think a European partner is gonna happen
0 · Reply
teachutrades
teachutrades Mar. 13 at 1:10 PM
$SNGX HUGE potential here!!!
0 · Reply
ZacksSCR
ZacksSCR Mar. 12 at 2:09 PM
$SNGX: Important Upcoming Readouts in Phase 3 CTCL Study https://buff.ly/XpjledW
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 10 at 6:07 PM
BioMedNewsBreaks – $SNGX SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease https://ibn.fm/dkcXA
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 10 at 11:44 AM
$SNGX Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
0 · Reply
frankyboyz
frankyboyz Mar. 10 at 11:41 AM
SNGX : Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency $SNGX 10m float 1.3/1.4 break play 1 has to hold
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Mar. 10 at 3:33 AM
🌅 Watchlist part 3 ✅ $KIDZ 1/50 reverse split (RS), new price ~3 ✅ $ELAB 1/6 RS, new price ~4.38 ✅ $ARTL 1/3 RS, new price ~3.81 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $SNGX $HCAT still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 9 at 7:35 PM
$SNGX Secures Key European Milestone for Dusquetide Development https://ibn.fm/LxrLK https://ibn.fm/lvKIs
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Mar. 9 at 1:25 PM
🌅 Watchlist part 2 ✅ $MGRX low $0.30 support, if above $0.40, have potential to $0.50 / $0.60 ✅ $TURB multiday runner, low $4 support, if above $4.50, have potential to $4.80 / $5.30, does have mixed shelf ✅ $SCKT low $1 support, if above $1.40, have potential to $1.70 / $1.80 ✅ $RPGL low $1.20 support, if above $1.40, have potential to $1.60 / $1.70 ⚠️ The above tickers are not ideal for swing accumulation at current price ⚠️ ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support ⚠️ Avoid chasing long into strength near resistance. ⏳⏳ $SNGX HCAT still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Mar. 9 at 3:02 AM
🌅 Watchlist part 3 ✅ $DTCK 1/20 RS, new price ~ $1.40 ✅ $RVPH 1/20 RS, new price ~ $3.60 🚨 The above tickers are not ideal for swing accumulation at current price 🚨 ✅ Ideal long entry near low current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $SNGX $HCAT still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
1 · Reply
JB20901
JB20901 Mar. 8 at 1:18 PM
$SNGX Mcpatience
0 · Reply